What do systematic reviews say?

Rituximab vs placebo

It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).

• Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
  OR 1.55 [0.06, 39.15]
  1 study · 104 participants
  Very low